ABSTRACT
From our very first engagement in the pharmaceutical industry to the present day, our clients have asked for help evaluating the markets for drugs that treat chronic illnesses. The reasons for this recurrent request are simple; chronic diseases affect roughly half of the U.S. adult population, and spending to treat such conditions represents over 70% of all healthcare expenditures.1,2 Aging of the baby boom generation, longer life spans, and the push for increased healthcare coverage virtually guarantee that chronic illnesses will continue to be a huge part of the pharmaceutical market landscape over the next few decades.
